カテゴリ： Allied Market Research, 世界, 医療/バイオ

転移性がん治療薬のグローバル市場（2023-2032）：化学療法、ホルモン療法、標的療法、免疫療法

■ 英語タイトル：Metastatic Cancer Drugs Market By Therapy (Chemotherapy, Hormonal therapy, Targeted therapy, Immunotherapy), By Indication (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Others), By Distribution channel (Hospital Pharmacies, Drug Store and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2023-2032

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23SEP175）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23SEP175
■ 発行日：2023年6月
■ 調査対象地域：グローバル
■ 産業分野：生命科学
■ ページ数：313
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[転移性がん治療薬のグローバル市場（2023-2032）：化学療法、ホルモン療法、標的療法、免疫療法]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

転移性がん治療薬市場は、2022年には677億ドルと評価され、2023年から2032年までの年平均成長率は7.3%を示し、2032年には1,369億ドルに達すると推定されています。転移性がんはステージIVがんとも呼ばれ、がんが元の部位（原発腫瘍）から血流やリンパ系を通じて体の他の部位に転移した状態を表す用語です。進行がんのステージであり、治療や予後の面で大きな困難を伴います。がん細胞は原発巣から離脱すると、血流やリンパ管を通って離れた臓器や組織に移動します。新しい場所に到達したがん細胞は成長を開始し、転移として知られるプロセスで新たな腫瘍を形成します。新しい腫瘍は転移または二次性腫瘍と呼ばれます。例えば、乳がんが肺に転移した場合、肺に生じる腫瘍は転移性乳がんと呼ばれ、肺がんとは呼ばれません。
さらに、転移性がんは、乳がん、肺がん、大腸がん、前立腺がん、黒色腫など、さまざまな種類の原発腫瘍から発生する可能性があります。最も一般的な転移部位は、肺、肝臓、骨、脳、リンパ節などです。また、転移がんは限局がんに比べてより重篤で困難な病期と考えられています。予後が悪く、治療の選択肢も少なくなります。がん細胞が遠隔部位に広がることで、病気を完全に根絶することが難しくなります。転移性がんの症状や徴候は、転移の場所や大きさによって異なります。一般的な症状としては、体重減少、特定部位の持続的な痛み、息切れ、疲労感、脳が侵された場合の神経症状などがあります。

転移性がん治療薬市場の成長を促進する主な要因は、研究開発の進歩、転移性がんの有病率の増加、個別化医療に対する需要の急増、老人人口の増加、政府の支援策です。世界的な転移性がんの罹患率と有病率の急増は、市場成長の重要な推進力となっています。例えば、乳がん研究財団（BCRF）が2022年に発表した記事によると、米国では女性の6～10％がステージ4の乳がんと診断され、早期乳がんと診断された女性の30％近くが転移性がんに罹患する可能性があります。転移性がんと診断される患者数の急増に伴い、進行期がん特有の課題に対処する効果的な薬剤の開発と入手が必要となっています。

さらに、進行中の研究開発努力が転移性がん治療薬市場の成長を促進する上で重要な役割を果たしています。分子生物学、ゲノミクス、標的治療における発見により、転移を引き起こす分子メカニズムを特異的に標的とする革新的な薬剤が開発されています。創薬技術の進歩により、新たな創薬標的が同定され、これらの標的を選択的に阻害する化合物が開発されたことで、有効性の向上と毒性の軽減が実現しました。例えば、チロシンキナーゼ阻害剤（TKI）などの標的療法は、がんの増殖と進行に関与する特定の分子標的を阻害することで、特定のタイプの転移性がんの治療に顕著な成功を示しています。このような進歩は、市場においてより新しく、より効果的な薬剤の需要を高める原動力となっています。

さらに、研究開発では、補完的な作用機序を持つ複数の薬剤を同時に使用する併用療法の開発に注力しています。併用療法は治療効果を高め、薬剤耐性を克服し、患者の予後を改善します。さらに、新しい薬物送達システムの開発により、転移性がん治療薬の有効性と安全性が向上します。ナノテクノロジーに基づく製剤、標的薬物送達システム、併用療法などの高度な薬物送達技術は、より優れた薬物標的化、毒性の低減、治療成績の改善を可能にします。これらの技術革新は、転移性がん治療薬市場の成長に貢献しています。さらに、転移性がん治療薬の研究、開発、利用しやすさのための資金提供などの政府のイニシアチブは、市場の成長を促進すると予想されます。公的資金、助成金、学術機関や製薬企業との提携は、新規薬剤や治療アプローチの発見と開発を促進します。これらのイニシアチブは、手頃な価格の転移性がん治療薬への患者アクセスを改善することを目的としており、市場の成長をさらに促進します。

さらに、転移性がんとその治療選択肢に関する認識と教育の高まりも市場の成長に寄与しています。患者や介護者の支援団体、啓発キャンペーン、教育プログラムは、転移性がんの早期発見、適時診断、適切な治療の促進に役立ちます。このような意識の高まりは、転移性がん治療薬の需要を促進し、患者の転帰を改善します。転移性がん治療薬市場は、治療法、適応症、流通チャネル、地域によって区分されます。治療法ベースでは、市場は化学療法、ホルモン療法、標的療法、免疫療法に分類されます。適応症別では、乳がん、肺がん、前立腺がん、大腸がん、メラノーマ、その他に分類されます。流通チャネル別では、病院薬局、ドラッグストア・小売薬局、オンラインプロバイダーに分類されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他欧州）、アジア太平洋（日本、中国、オーストラリア、インド、韓国、その他アジア太平洋）、LAMEA（ブラジル、南アフリカ、サウジアラビア、その他LAMEA）で分析されています。

世界の転移性がん治療薬市場で事業を展開する主な主要企業は、Novartis AG, Pfizer Inc., AstraZeneca, Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Amgen Inc., Sanofi S.A. and F. Hoffmann-La Roche Ltd.です。主要企業は、製品ポートフォリオを拡大するために、提携、製品上市、新製品開発、製品承認などの戦略を採用しています。

ステークホルダーにとっての主なメリット
本レポートは、2022年から2032年までの転移性がん治療薬市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、優勢な転移性がん治療薬市場機会を特定します。
主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
転移性がん治療薬市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
地域別および世界別の転移性がん治療薬市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

主要市場セグメント
治療法別
化学療法
ホルモン療法
標的療法
免疫療法

適応症別
乳がん
肺がん
前立腺がん
大腸がん
メラノーマ
その他

販売チャネル別
病院薬局
ドラッグストア・小売薬局
オンラインプロバイダー

地域別
北米
米国
カナダ
メキシコ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
アジア太平洋
日本
中国
インド
オーストラリア
韓国
その他のアジア太平洋地域
LAMEA
ブラジル
サウジアラビア
南アフリカ
その他の地域

主要市場プレイヤー
○ Amgen Inc.
○ AstraZeneca plc
○ Bristol-Myers Squibb Company
○ Eli Lilly and Company.
○ F. Hoffmann-La Roche Ltd.
○ Johnson & Johnson
○ Merck & Co., Inc.
○ Novartis AG
○ Pfizer Inc.
○ Sanofi S.A.

第1章：イントロダクション
第2章：エグゼクティブサマリー
第3章：市場概要
第4章：転移性がん治療薬市場、治療法別
第5章：転移性がん治療薬市場、疾患別
第6章：転移性がん治療薬市場、流通チャネル別
第7章：転移性がん治療薬市場、地域別
第8章：競争状況
第9章：企業情報

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. High bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. High bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Advancements in cancer detection and diagnosis
3.4.1.2. Increase in prevalence of metastatic cancer
3.4.1.3. Surge in adoption of personalized medicine

3.4.2. Restraints
3.4.2.1. Adverse effects associated with the use of cancer drugs

3.4.3. Opportunities
3.4.3.1. High growth potential in untapped emerging economies
3.4.3.2. Increase in number of pipeline drugs

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: METASTATIC CANCER DRUGS MARKET, BY THERAPY
4.1. Overview
4.1.1. Market size and forecast
4.2. Chemotherapy
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Hormonal therapy
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Targeted therapy
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Immunotherapy
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: METASTATIC CANCER DRUGS MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Breast Cancer
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Lung Cancer
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Prostate Cancer
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Colorectal Cancer
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Melanoma
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
5.7. Others
5.7.1. Key market trends, growth factors and opportunities
5.7.2. Market size and forecast, by region
5.7.3. Market share analysis by country
CHAPTER 6: METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Drug Store and Retail Pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online Providers
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: METASTATIC CANCER DRUGS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Therapy
7.2.3. Market size and forecast, by Indication
7.2.4. Market size and forecast, by Distribution channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Therapy
7.2.5.1.3. Market size and forecast, by Indication
7.2.5.1.4. Market size and forecast, by Distribution channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Therapy
7.2.5.2.3. Market size and forecast, by Indication
7.2.5.2.4. Market size and forecast, by Distribution channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Therapy
7.2.5.3.3. Market size and forecast, by Indication
7.2.5.3.4. Market size and forecast, by Distribution channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Therapy
7.3.3. Market size and forecast, by Indication
7.3.4. Market size and forecast, by Distribution channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Therapy
7.3.5.1.3. Market size and forecast, by Indication
7.3.5.1.4. Market size and forecast, by Distribution channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Therapy
7.3.5.2.3. Market size and forecast, by Indication
7.3.5.2.4. Market size and forecast, by Distribution channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Therapy
7.3.5.3.3. Market size and forecast, by Indication
7.3.5.3.4. Market size and forecast, by Distribution channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Therapy
7.3.5.4.3. Market size and forecast, by Indication
7.3.5.4.4. Market size and forecast, by Distribution channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Therapy
7.3.5.5.3. Market size and forecast, by Indication
7.3.5.5.4. Market size and forecast, by Distribution channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Therapy
7.3.5.6.3. Market size and forecast, by Indication
7.3.5.6.4. Market size and forecast, by Distribution channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Therapy
7.4.3. Market size and forecast, by Indication
7.4.4. Market size and forecast, by Distribution channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Therapy
7.4.5.1.3. Market size and forecast, by Indication
7.4.5.1.4. Market size and forecast, by Distribution channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Therapy
7.4.5.2.3. Market size and forecast, by Indication
7.4.5.2.4. Market size and forecast, by Distribution channel
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Therapy
7.4.5.3.3. Market size and forecast, by Indication
7.4.5.3.4. Market size and forecast, by Distribution channel
7.4.5.4. Australia
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Therapy
7.4.5.4.3. Market size and forecast, by Indication
7.4.5.4.4. Market size and forecast, by Distribution channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Therapy
7.4.5.5.3. Market size and forecast, by Indication
7.4.5.5.4. Market size and forecast, by Distribution channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Therapy
7.4.5.6.3. Market size and forecast, by Indication
7.4.5.6.4. Market size and forecast, by Distribution channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Therapy
7.5.3. Market size and forecast, by Indication
7.5.4. Market size and forecast, by Distribution channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Therapy
7.5.5.1.3. Market size and forecast, by Indication
7.5.5.1.4. Market size and forecast, by Distribution channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Therapy
7.5.5.2.3. Market size and forecast, by Indication
7.5.5.2.4. Market size and forecast, by Distribution channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Therapy
7.5.5.3.3. Market size and forecast, by Indication
7.5.5.3.4. Market size and forecast, by Distribution channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Therapy
7.5.5.4.3. Market size and forecast, by Indication
7.5.5.4.4. Market size and forecast, by Distribution channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Bristol-Myers Squibb Company
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Merck & Co., Inc.
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. AstraZeneca plc
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Novartis AG
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Eli Lilly and Company.
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Pfizer Inc.
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. F. Hoffmann-La Roche Ltd.
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. Johnson & Johnson
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Amgen Inc.
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Sanofi S.A.
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance

LIST OF TABLES
TABLE 01. GLOBAL METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 02. METASTATIC CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 03. METASTATIC CANCER DRUGS MARKET FOR HORMONAL THERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 04. METASTATIC CANCER DRUGS MARKET FOR TARGETED THERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 05. METASTATIC CANCER DRUGS MARKET FOR IMMUNOTHERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 06. GLOBAL METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 07. METASTATIC CANCER DRUGS MARKET FOR BREAST CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 08. METASTATIC CANCER DRUGS MARKET FOR LUNG CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 09. METASTATIC CANCER DRUGS MARKET FOR PROSTATE CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 10. METASTATIC CANCER DRUGS MARKET FOR COLORECTAL CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 11. METASTATIC CANCER DRUGS MARKET FOR MELANOMA, BY REGION, 2022-2032 ($MILLION)
TABLE 12. METASTATIC CANCER DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 13. GLOBAL METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 14. METASTATIC CANCER DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 15. METASTATIC CANCER DRUGS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 16. METASTATIC CANCER DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
TABLE 17. METASTATIC CANCER DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 20. NORTH AMERICA METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 21. NORTH AMERICA METASTATIC CANCER DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 22. U.S. METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 23. U.S. METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 24. U.S. METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 25. CANADA METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 26. CANADA METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 27. CANADA METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 28. MEXICO METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 29. MEXICO METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 30. MEXICO METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 31. EUROPE METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 32. EUROPE METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 33. EUROPE METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 34. EUROPE METASTATIC CANCER DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 35. GERMANY METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 36. GERMANY METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 37. GERMANY METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 38. FRANCE METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 39. FRANCE METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 40. FRANCE METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 41. UK METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 42. UK METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 43. UK METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 44. ITALY METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 45. ITALY METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 46. ITALY METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 47. SPAIN METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 48. SPAIN METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 49. SPAIN METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 50. REST OF EUROPE METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 51. REST OF EUROPE METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 52. REST OF EUROPE METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 53. ASIA-PACIFIC METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 54. ASIA-PACIFIC METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 55. ASIA-PACIFIC METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 56. ASIA-PACIFIC METASTATIC CANCER DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 57. JAPAN METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 58. JAPAN METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 59. JAPAN METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 60. CHINA METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 61. CHINA METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 62. CHINA METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 63. INDIA METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 64. INDIA METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 65. INDIA METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 66. AUSTRALIA METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 67. AUSTRALIA METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 68. AUSTRALIA METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 69. SOUTH KOREA METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 70. SOUTH KOREA METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 71. SOUTH KOREA METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 73. REST OF ASIA-PACIFIC METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 74. REST OF ASIA-PACIFIC METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 75. LAMEA METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 76. LAMEA METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 77. LAMEA METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 78. LAMEA METASTATIC CANCER DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 79. BRAZIL METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 80. BRAZIL METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 81. BRAZIL METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 82. SAUDI ARABIA METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 83. SAUDI ARABIA METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 84. SAUDI ARABIA METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 85. SOUTH AFRICA METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 86. SOUTH AFRICA METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 87. SOUTH AFRICA METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 88. REST OF LAMEA METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 89. REST OF LAMEA METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 90. REST OF LAMEA METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 91. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
TABLE 92. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 93. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
TABLE 94. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 95. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES
TABLE 96. MERCK & CO., INC.: KEY EXECUTIVES
TABLE 97. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 98. MERCK & CO., INC.: PRODUCT SEGMENTS
TABLE 99. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 100. MERCK & CO., INC.: KEY STRATERGIES
TABLE 101. ASTRAZENECA PLC: KEY EXECUTIVES
TABLE 102. ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 103. ASTRAZENECA PLC: PRODUCT SEGMENTS
TABLE 104. ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 105. ASTRAZENECA PLC: KEY STRATERGIES
TABLE 106. NOVARTIS AG: KEY EXECUTIVES
TABLE 107. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 108. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 109. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 110. NOVARTIS AG: KEY STRATERGIES
TABLE 111. ELI LILLY AND COMPANY.: KEY EXECUTIVES
TABLE 112. ELI LILLY AND COMPANY.: COMPANY SNAPSHOT
TABLE 113. ELI LILLY AND COMPANY.: PRODUCT SEGMENTS
TABLE 114. ELI LILLY AND COMPANY.: PRODUCT PORTFOLIO
TABLE 115. ELI LILLY AND COMPANY.: KEY STRATERGIES
TABLE 116. PFIZER INC.: KEY EXECUTIVES
TABLE 117. PFIZER INC.: COMPANY SNAPSHOT
TABLE 118. PFIZER INC.: PRODUCT SEGMENTS
TABLE 119. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 120. PFIZER INC.: KEY STRATERGIES
TABLE 121. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 122. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 123. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 124. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 125. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
TABLE 126. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 127. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 128. JOHNSON & JOHNSON: PRODUCT SEGMENTS
TABLE 129. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 130. JOHNSON & JOHNSON: KEY STRATERGIES
TABLE 131. AMGEN INC.: KEY EXECUTIVES
TABLE 132. AMGEN INC.: COMPANY SNAPSHOT
TABLE 133. AMGEN INC.: PRODUCT SEGMENTS
TABLE 134. AMGEN INC.: PRODUCT PORTFOLIO
TABLE 135. AMGEN INC.: KEY STRATERGIES
TABLE 136. SANOFI S.A.: KEY EXECUTIVES
TABLE 137. SANOFI S.A.: COMPANY SNAPSHOT
TABLE 138. SANOFI S.A.: PRODUCT SEGMENTS
TABLE 139. SANOFI S.A.: PRODUCT PORTFOLIO

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 乳がん治療薬のグローバル市場（2023-2032）：化学療法、ホルモン療法、標的療法、免疫療法
  • 抗がん剤の世界市場2022：化学療法、標的療法、免疫療法、ホルモン療法（生物療法）、その他
  • がん用個別化医療のグローバル市場展望 2023年-2029年：免疫療法、標的療法、化学療法、ホルモン療法、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23SEP175 )"転移性がん治療薬のグローバル市場（2023-2032）：化学療法、ホルモン療法、標的療法、免疫療法" (英文：Metastatic Cancer Drugs Market By Therapy (Chemotherapy, Hormonal therapy, Targeted therapy, Immunotherapy), By Indication (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Others), By Distribution channel (Hospital Pharmacies, Drug Store and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2023-2032)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。